The 3␤-hydroxy-⌬ 5 -C 27 -steroid oxidoreductase (C 27 3␤-HSD) is a membrane-bound enzyme of the endoplasmic reticulum that catalyzes an early step in the synthesis of bile acids from cholesterol. Subjects with autosomal recessive mutations in the encoding gene, HSD3B7, on chromosome 16p11.2-12 fail to synthesize bile acids and develop a form of progressive liver disease characterized by cholestatic jaundice and malabsorption of lipids and lipid-soluble vitamins from the gastrointestinal tract. The gene encoding the human C 27 3␤-HSD enzyme was isolated previously, and a 2-bp deletion in exon 6 of HSD3B7 was identified in a well characterized subject with this disorder. Here, we report a molecular analysis of 15 additional patients from 13 kindreds with C 27 3␤-HSD deficiency. Twelve different mutations were identified in the HSD3B7 gene on chromosome 16p11.2-12. Ten mutations were studied in detail and shown to cause complete loss of enzyme activity and, in two cases, alterations in the size or amount of the transcribed mRNA. Mutations were inherited in homozygous form in 13 subjects from 10 families and compound heterozygous form in four subjects from three families. We conclude that a diverse spectrum of mutations in the HSD3B7 
T HE CONVERSION OF cholesterol into bile acids is es-
sential for the maintenance of cholesterol homeostasis, regulation of hepatic function, and absorption of fats and fat-soluble vitamins from the gastrointestinal tract. Inherited mutations that decrease the synthesis of bile acids or their transport cause a disorder beginning in infants and consisting of impairment of liver function because of decreased bile flow (cholestasis) and lipid and vitamin malabsorption.
The genetic basis of neonatal cholestasis is heterogeneous. Mutations in three genes encoding primary bile acid biosynthetic enzymes have so far been identified as causes of this disease. These include the oxysterol 7␣-hydroxylase gene (CYP7B1) (1) located on chromosome 8q21.3, the 3-oxo-⌬ 4 -steroid 5␤-reductase gene (AKR1D1) (2) on chromosome 7q32-33, and the 3␤-hydroxy-⌬ 5 -C 27 -steroid oxidoreductase (C 27 3␤-HSD) gene (HSD3B7) (3, 4) ) on chromosome 16p11. 2-12. Each of the encoded enzymes catalyzes an early step in the biosynthetic pathway, and, consequently, their loss prevents the synthesis of adequate levels of primary bile acids required for the promotion of bile secretion and intraluminal fat absorption.
Deficiencies in bile acid transport causing neonatal cholestasis also have been traced to mutations in three genes, including FIC1 on chromosome 18q21 (5) , ABCB11 on chromosome 2q24 (6) , and ABCB4 on chromosome 7q21.1 (7) . The product of FIC1 is a P-type ATPase expressed on the apical membranes of enterocytes in the small intestine and to a lesser extent in liver parenchyma. The ABCB11 gene product often is referred to as the bile salt export protein and is expressed on the hepatocyte canalicular membrane. The protein specified by the ABCB4 gene, originally designated the multidrug resistance 3 protein, is located on the canalicular membrane of the hepatocyte and is active in the transport of phospholipids. Both ABCB11 and ABCB4 are members of a large family of proteins that transport small molecules out of cells (8, 9) .
Although neonatal cholestasis is genetically heterogeneous, the manifestations of loss of either a biosynthetic enzyme or transport protein are similar. Affected individuals present at birth or in early childhood with cholestatic jaundice, fat-soluble vitamin deficiency, and acholic or fatty stools (steatorrhea). Serum transaminases are usually elevated, and a conjugated hyperbilirubinemia is often present. Liver biopsies may reveal nonspecific changes, but giant cell transformation of hepatocytes, inflammation, fibrosis, and canalicular and hepatocyte cholestasis is usual (10 -12) . Chemical analysis of body fluids reveals an accumulation of atypical bile acids and sterol intermediates. Bile acid biosynthetic defects, in particular C 27 3␤-HSD deficiency, may also cause late-onset chronic cholestasis, and in these individuals the clinical history generally reveals a pattern of mildly elevated transaminases in infancy that often resolves only to reemerge later and an early-onset of vitamin Ddeficient rickets (13) .
Despite a shared clinical presentation, the various genetic forms of neonatal cholestasis require different treatments. Loss of either the C 27 3␤-HSD or the 3-oxo-⌬ 4 -steroid 5␤-reductase enzyme is treated by oral administration of bile acids (11, 14 -16) , a therapy that is both effective and relatively free of side effects. In contrast, loss of the oxysterol 7␣-hydroxylase enzyme (1) or various bile acid transporters (17) requires liver transplantation. The marked differences in the treatment regimens for the various forms of inherited neonatal cholestasis underscore the importance of defining the molecular basis of the disease in individual patients (18) .
In this study, we describe the molecular basis of neonatal cholestasis caused by C 27 3␤-HSD deficiency in a cohort of patients diagnosed by mass spectrometric analyses in Paris and Cincinnati (19) . Affected individuals in this cohort are either homozygous or compound heterozygous carriers of 12 different mutations in the HSD3B7 gene, many of which are shown to inactivate the encoded enzyme. Notwithstanding this molecular heterogeneity, diagnosis of the disease and subsequent treatment with bile acids led to favorable outcomes in most patients.
Subjects and Methods
Institutional Review Board approvals were obtained from the University of Texas Southwestern Medical Center, Bicêtre University Hospital, King Faisal Specialist Hospital, St. Joseph Hospital, and the Cincinnati Children's Hospital. Informed consent was obtained from all subjects, and consent forms are maintained at the above institutions. Oral bile acid therapy with cholic acid was provided as an investigational new drug approved by the Food and Drug Administration. A preliminary medical history of probands from families A-E has been reported (19) . Salient clinical features of these and other affected individuals in the cohort analyzed here are summarized in Table 1 .
Materials and methods
Genomic DNA extraction and sequencing. Human genomic DNA was isolated from white blood cells or cultured fibroblasts using Puregene DNA isolation kits (Gentra Systems, Minneapolis, MN). Exons of the HSD3B7 gene were amplified by PCR using the Advantage-GC genomic PCR kit (CLONTECH Laboratories, Inc., Palo Alto, CA). DNA products were purified by centrifugation through Centricon YM-100 filter devices (Millipore Corp., Billerica, MA) and subjected to sequence analysis using a thermostable DNA polymerase and fluorescently labeled nucleoside terminators (Applied Biosystems, Foster City, CA). Data were collected on an automated DNA sequencer (Applied Biosystems).
Biochemical analysis of HSD3B7 alleles.
A fragment of DNA corresponding to nucleotides 181,011 through 178,216 of the Homo sapiens chromosome 16 working draft sequence (accession no. NT_024826.3) that encompassed exons 1 through 6 of the HSD3B7 gene was amplified from each proband's genomic DNA. The primers were designed to introduce an SalI site at the 5Ј-end of the amplified DNA and an NotI site at the 3Ј-end. Amplification reactions contained 2.5 U Pfu Turbo DNA polymerase (Stratagene, La Jolla, CA) and 5% (vol/vol) dimethylsulfoxide. The resulting DNA fragment was ligated into the pCMV6 expression vector (GenBank accession no. 239250), and the presence of the appropriate b This is patient MU1, the index case in whom C 27 3␤-HSD deficiency was first described (3). c Liver damage (cirrhosis) before diagnosis was extensive in these patients, and bile acid therapy was unsuccessful. Both underwent orthotopic liver transplantation. mutation was confirmed by DNA sequence analysis. A small fragment of DNA containing each mutation was then substituted for the corresponding segment of the normal gene harbored in pCMV6.
Human embryonic kidney (HEK) 293 cells (CRL 1573; American Type Culture Collection, Manassas, VA) were plated at a density of 4 ϫ 10 5 cells per 60-mm dish in 2.5 ml DMEM containing 1 g/liter glucose, 10% (vol/vol) fetal calf serum, 100 U/ml penicillin, and 100 g/ml streptomycin sulfate. Two days after plating, cells were transfected using the FuGENE6 reagent (Roche Diagnostics, Indianapolis, IN) with a mixture of plasmid DNAs. The mixture included 1.8 g pCMV6-hCYP7B1, encoding the human oxysterol 7␣-hydroxylase enzyme (1), 1.8 g pCMV6-HSD3B7 (mutant or normal), and 0.4 g pVA-1, a vector expressing the adenovirus type 5 VA1 gene (20) . At 16 h post transfection, the Fu-GENE6-containing medium was replaced with fresh DMEM medium supplemented with 0.0152 m [
3 H]cholest-5-ene-3␤,25-diol (25-hydroxycholesterol, 78.5 Ci/mmol, NEN Life Science Products, Boston, MA), and 1.0 m 25-hydroxycholesterol. The medium was harvested 8 h later, and lipids were extracted using 8 ml Folch reagent (chloroform: methanol; 2:1, vol/vol) per dish. The organic extract was lyophilized and lipids were dissolved in 50 l acetone and resolved by thin-layer chromatography on pre-cored LK5DF silica gel plates (Whatman, Clifton, NJ) in a solvent system of toluene:ethyl acetate (2:3, vol/vol). Radioactive sterols were detected by phosphor imaging on a BAS1000 machine (Fuji Photo Film Co., Ltd. Medical Systems, Tokyo, Japan) or autoradiography using X-OMAT AR film (Kodak, Rochester, NY). The detection limit for this enzymatic assay was 0.05-0.2 pmol C 27 3␤-HSD product/min per milligram cell protein.
Analysis of HSD3B7 RNA. HEK 293 cells were transfected as described above with pCMV6 constructs harboring either a normal C 27 3␤-HSD gene fragment or a variant allele. At 24 h after transfection, total cellular RNA was isolated using RNA STAT-60 (Tel-Test "B" Inc.) and poly(A) ϩ -enriched mRNA was isolated by oligo(dT)-cellulose chromatography (mRNA purification kit, Amersham Pharmacia Biotech, Piscataway, NJ). Aliquots of purified mRNA (5 g) were separated by electrophoresis through 1.4% (wt/vol) agarose gels and subjected to blot hybridization using standard procedures (21) . Radiolabeled probes were derived from a human C 27 3␤-HSD cDNA (GenBank accession no. AF277719; Ref. 4) and ␤-actin cDNA (GenBank accession no. NM_001101; 22).
Database access. Accession numbers and URLs for data in this article are: GenBank, http://www.ncbi.nih.gov/GenBank/[for human CYP7B1 cDNA (accession no. AF029403), pCMV6 (accession no. AF029403), C 27 3␤-HSD cDNA (accession no. AF277719), human C 27 3␤-HSD gene (accession no. NT_024826.3), human ␤-actin (accession no. NM_001101)]; Online Mendelian Inheritance of Man (OMIM), http://www.ncbi.nlm. nih.gov/omim/[for giant cell hepatitis, neonatal (MIM231100), oxy-
Results

HSD3B7 mutations in patients with neonatal cholestasis
The diagnosis of C 27 3␤-HSD deficiency in probands was based on clinical presentation and mass spectrometric identification in urine of the signature 3␤-hydroxy-⌬ 5 bile acids characteristic of the biochemical defect (Fig. 1) . To confirm the diagnosis and establish the molecular basis of the disorder, genomic DNA was isolated from the white blood cells of probands and, when possible, other affected and unaffected family members. The data of Fig. 2, A and B, show two extended Arabic pedigrees in which C 27 3␤-HSD deficiency segregated as an apparent autosomal recessive trait. This inheritance pattern was confirmed in family J by DNA sequence analysis of exon 6 in which a 2-bp deletion (1057, ⌬CT) was detected in heterozygous form in the parents and unaffected carrier offspring and in homozygous form in the proband and an affected sibling (Fig. 2B) .
Amplifying a 3-kb segment that encompassed the six exons and five introns of the gene and subjecting this DNA to sequence analysis identified additional mutations in HSD3B7. These experiments revealed 12 different mutations segregating in the 13 kindreds analyzed (Fig. 3) . In 10 of the 12 families, including all of those with confirmed or suspected consanguinity, a single mutation was found in homozygous form. The probands in the remaining three kindreds were compound heterozygotes who inherited two different mutations in the HSD3B7 gene. The molecular genetic features of this cohort are summarized in Table 2 .
Individual mutations mapped to four exons and two introns of HSD3B7 and included one nonsense mutation, two missense mutations, five small deletions of one to three base pairs, two small insertions of one to two base pairs, and two mutations that altered consensus splice junction sequences (Fig. 4) .
Analysis of HSD3B7 mRNA
The effects of 10 of these mutations on the size and amount of mRNA transcribed from the mutant HSD3B7 alleles were determined. Individual mutations were recreated by sitedirected mutagenesis in a pCMV expression vector containing a 3-kb segment of genomic DNA encompassing the gene. Transcription from these minigene constructs is initiated within a cytomegalovirus promoter and terminated within sequences of the human GH gene, and splicing signals are supplied by the introns of the HSD3B7 gene. Individual plasmid DNAs were introduced into HEK 293 cells by transfection, and levels of mature C 27 3␤-HSD mRNA were determined by blot hybridization.
The data of Fig. 5 show that cells transfected with the pCMV vector alone do not produce a C 27 3␤-HSD mRNA (lane 1), whereas those transfected with a construct containing the normal gene synthesize an mRNA that is approximately 1.5 kb in length (lane 2). All but two of the eight mutant genes analyzed in this experiment produced a sim- ilarly sized mRNA in approximately the same amount. The two exceptions were genes containing the 132, iCC mutation in exon 1 (lane 5), and the 713-1, G3 A mutation in the splice acceptor site of intron 5 (lane 9). Little or no mature C 27 3␤-HSD mRNA was detected in cells transfected with the 132, iCC mutation, presumably because this lesion leads to rapid turnover of the transcribed mRNA. The 713-1, G3 A mutation gave rise to a small amount of normal-sized mRNA and a larger RNA of approximately 2.7 kb. Although not tested directly, the size of the larger RNA suggested that it might contain sequences corresponding to the unspliced intron 5 in addition to those derived from exons 1 through 5. Constructs containing two additional HSD3B7 mutations, 63, ⌬AG and 1057, ⌬CT, were analyzed in a separate experiment and found to produce mRNAs that were similar in size and amount to those derived from the normal gene (data not shown). The effects of the G19S and 140, ⌬TC mutations on steady-state mRNA levels were not determined.
Analysis of enzyme activity
The C 27 3␤-HSD enzyme catalyzes the isomerization and oxidation of 7␣-hydroxylated sterol intermediates that arise in the pathways of bile acid synthesis. These substrates are neither commercially available nor readily synthesized in radiolabeled form. To overcome these challenges, an assay was employed in which 7␣-hydroxylated substrates are produced in situ by incubating cells transfected with cDNAs encoding sterol 7␣-hydroxylase enzymes with radiolabeled sterol precursors (4). For example, incubation of HEK 293 cells transfected with the CYP7B1 oxysterol 7␣-hydroxylase cDNA with 25-hydroxycholesterol, resulted in the production of [ 3 H]cholest-5-ene-3␤,7␣,25-triol (Fig. 6,  lane 2) , a 7␣-hydroxylated substrate of the C 27 3␤-HSD enzyme. Monitoring the conversion of this sterol into 7␣,25-dihydroxycholest-4-ene-3-one, in cells cotransfected with cDNA expression vectors encoding both CYP7B1 and C 27 3␤-HSD, allowed measurement of C 27 3␤-HSD enzyme activity (lane 3).
When expression plasmids containing eight of the mutant HSD3B7 genes were transfected into HEK 293 cells together with the CYP7B1 cDNA, little or no conversion of [ 3 H]cholest-5-ene-3␤,7␣,25-triol into the C 27 3␤-HSD product was observed (Fig. 6, lanes 4 -11) . In separate experiments, minigenes harboring the 63, ⌬AG and 1057, ⌬CT mutations also failed to encode an active enzyme when introduced into HEK 293 cells (data not shown). These results indicated that 10 of the 12 mutations identified in the HSD3B7 gene were null alleles, at least as judged at the level of sensitivity (0.05-0.2 pmol C 27 3␤-HSD product/min per milligram cell protein) of the biochemical assay employed. The effects of the two re- maining mutations (G19S and 140, ⌬TC) were not determined. Antibodies directed against the human C 27 3␤-HSD were not available; thus, we were unable to determine which of the mutant alleles directed the synthesis of a stable protein.
Discussion
We describe a genetic and molecular analysis in 16 patients from 13 families with a form of neonatal cholestasis arising from C 27 3␤-HSD deficiency. A diverse spectrum of point mutations, small insertions, and deletions in the HSD3B7 genes of affected individuals are present in homozygous and compound heterozygous form. These lesions variably affect the steady-state levels of mRNA transcribed from the mutant genes and in every case tested impair synthesis of an active C 27 3␤-HSD enzyme. In turn, this loss prevents the synthesis of bile acids and disrupts liver function.
It has been recognized since 1987 that this disorder is the result of a defect in an early step of bile acid synthesis (3). We previously showed that the molecular basis of this genetic disease in one well-studied patient from Saudi Arabia was due to a mutation in the HSD3B7 gene (4). The present study reveals that C 27 3␤-HSD deficiency is molecularly heterogeneous but genetically and therapeutically homogeneous. Molecular heterogeneity is indicated by the identification of 12 different mutations in the gene. The existence of so many different mutations does not complicate the molecular diagnosis of the disease because the HSD3B7 gene spans only 3 kb of DNA and is thus readily amplified and sequenced in its entirety. Genetic homogeneity is evident from the findings that all patients presenting with documented or suspected (see below) urinary accumulations of 3␤,7␣-dihydroxy-5-cholenoic acid and 3␤,7␣,12␣-trihydroxy-5-cholenoic acid inherited mutations in the HSD3B7 gene. Thus, unlike other bile acid biosynthetic enzymes, which exist in multiple isoforms (23) , there appears to be only one human gene that encodes C 27 3␤-HSD enzyme activity. A positive response to oral bile acids in all but two of the patients harboring different mutations shows the therapeutic homogeneity in C 27 3␤-HSD deficiency (Table 1) .
Mutations in HSD3B7 are rare and account for only a small percentage of neonatal cholestasis. In agreement with this low frequency, the probands from 10 of the 12 families studied here are true homozygotes who inherited identical mutations from both parents ( Table 2 ). The remaining three probands are compound heterozygotes. The 310, iC, E147K, 1057, ⌬CT, and 63, ⌬AG mutations were each present in two families, although there were no known shared histories between family pairs with the same mutation. This outcome suggests that these four mutations have been present for extended periods of time in the population, presumably existing in heterozygous form, because before the advent of bile acid therapy in the 20th century, individuals inheriting two mutations in the gene would have almost certainly perished before sexual maturation. The OMIM classifies C 27 3␤-HSD deficiency under the general heading of "giant cell hepatitis, neonatal" (OMIM 231100), together with various forms of neonatal hemochro- matosis caused by mutations in the steroid 5␤-reductase (AKR1D1) and oxysterol 7␣-hydroxylase (CYP7B1) genes of bile acid biosynthesis. The detailed clinical descriptions published in the literature together with the isolation of the encoding gene and the molecular analyses presented in this study and elsewhere (4) clearly indicate that C 27 3␤-HSD deficiency is a distinct disease entity.
The mutations identified here shed little light on the biochemistry of C 27 3␤-HSD, a 369-amino acid enzyme that is located in the endoplasmic reticulum membrane and has an unknown topology (4, 24) . Six of the 12 mutations map to the first two exons of the gene and are predicted to encode severely truncated proteins (Fig. 4) . As expected, these fragments do not possess enzyme activity (Fig. 6) . Similarly, the loss of one (1042, ⌬T) or two (1057, ⌬CT) base pairs from the last exon of the gene shifts the translational reading frame and eliminates enzyme activity. The protein encoded by the 1042, ⌬T mutation is composed of 341 amino acids from the normal protein fused to a 74-residue extension at the C terminus, whereas the 1057, ⌬CT mutation encodes a protein with the first 346 amino acids of the normal protein fused to a five-residue extension. In these cases, we do not know whether inactivation of the enzyme results from elimination of the normal C-terminal sequences or the addition of spurious amino acids at this end.
Only two potentially informative substitution mutations were identified in this survey. A G19S mutation in exon 1 was detected in the proband of family M while the manuscript was being reviewed and was not analyzed further. The proband of family F inherited a G-to-A transition mutation in exon 4 that results in the substitution of a lysine residue for glutamate at position 147 (E147K). Although an apparently stable mRNA of normal abundance was transcribed from the mutant gene (Fig. 5) , no enzyme activity was detected in the transfected cells (Fig. 6 ). The C 27 3␤-HSD is a member of a small family of enzymes that metabolize steroids and share sequence identity (4) . In sequence alignments of the seven known family members, the glutamate 147 residue of C 27 3␤-HSD is conserved in all of them, and this residue is shared also among the human, mouse, and rat C 27 3␤-HSD enzymes (4) . The preservation of this glutamate is suggestive of an important catalytic or structural role in these isomerase/ dehydrogenases and may explain why substitution with lysine inactivates the C 27 3␤-HSD enzyme in the proband. The glycine residue at position 19 also is conserved in all members of the 3␤-HSD enzyme family, and its loss may inactivate the C 27 3␤-HSD in the patient from family M.
Because all of the mutations analyzed in detail here were null alleles, we were unable to deduce any phenotypegenotype correlations in this cohort of C 27 3␤-HSD-deficient patients.
The availability of chemical and molecular methods to diagnose C 27 3␤-HSD deficiency raises questions concerning the relative merits of each procedure and whether there are cases in which one or the other method, or both, are needed for an unambiguous assignment. Ascertainment by chemical procedures requires sophisticated mass spectrometry that is available only in a small number of medical centers. Diagnosis by molecular methods is more widely possible but still requires access to appropriate facilities and expertise. While this manuscript was in review, we encountered a case in which both methods were required to make an accurate diagnosis of C 27 3␤-HSD deficiency. The mass spectra of samples obtained from the proband of family M were suggestive of the disorder but not definitive as a consequence of the advanced liver disease in this patient and the presence of obscuring ions arising from the ursodeoxycholic acid that was prescribed at the first signs of cholestasis. Analysis of the proband's DNA, which revealed two mutations in exon 1 of the gene (G19S and 140, ⌬TC) , was required to make an unambiguous assignment of the deficiency.
We conclude that mutations in the HSD3B7 gene underlie C 27 3␤-HSD deficiency, an autosomal recessive form of neonatal cholestasis. Preliminary data on long-term cholic acid therapy in children with this disorder show that it is an adequate and very effective treatment (11, 14 -16) . The identification of disease causing mutations will allow prenatal diagnosis within affected families and the initiation of cholic acid therapy in the immediate neonatal period.
